These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 33428309

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    BMC Endocr Disord; 2022 Sep 29; 22(1):241. PubMed ID: 36175881
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 7. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes.
    Zhuo M, Hawley CE, Paik JM, Bessette LG, Wexler DJ, Kim DH, Tong AY, Kim SC, Patorno E.
    JAMA Netw Open; 2021 Oct 01; 4(10):e2130762. PubMed ID: 34705014
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK, Bhatt DL, Montvida O.
    Eur Heart J; 2021 May 07; 42(18):1728-1738. PubMed ID: 33289789
    [Abstract] [Full Text] [Related]

  • 10. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M, D'Andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2235995. PubMed ID: 36219443
    [Abstract] [Full Text] [Related]

  • 11. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M, Caruso P, Scappaticcio L, Maiorino MI, Bellastella G, Capuano A, Esposito K, Giugliano D.
    Diabetes Obes Metab; 2024 Apr 03; 26(4):1492-1501. PubMed ID: 38234208
    [Abstract] [Full Text] [Related]

  • 12. Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review.
    Chai S, Niu Y, Liu F, Wu S, Yang Z, Sun F.
    J Diabetes Res; 2024 Apr 03; 2024():8145388. PubMed ID: 39072050
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM.
    Diabetes Metab; 2018 Mar 03; 44(2):112-120. PubMed ID: 29477373
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study.
    Sung HL, Hung CY, Tung YC, Lin CC, Tsai TH, Huang KH.
    Diabetes Metab Res Rev; 2024 Mar 03; 40(3):e3784. PubMed ID: 38402457
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review.
    Uhrig JL, Page SO, Mishriky BM, Patil SP, Powell JR, Sewell K, Mian MR, Cummings DM.
    J Clin Pharmacol; 2020 Aug 03; 60(8):980-991. PubMed ID: 32396236
    [Abstract] [Full Text] [Related]

  • 19. Concomitant Use of Sodium-Glucose Cotransporter 2 Inhibitors and Overactive Bladder Drugs and the Risk of Urinary Tract Infection.
    Bea S, Lee H, Park S, Cho YM, Choi WS, Bykov K, Shin JY.
    Clin Pharmacol Ther; 2024 May 03; 115(5):1132-1140. PubMed ID: 38284421
    [Abstract] [Full Text] [Related]

  • 20. Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
    Lee YC, Dong YH, Yang WS, Wu LC, Lin JW, Chang CH.
    Front Pharmacol; 2022 May 03; 13():869804. PubMed ID: 36176438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.